Yuanjia HU

Yuanjia HU
Associate Professor

Academic Qualifications

  • BSc, MSc, China Pharmaceutical University
  • MSc, PhD (Hon), University of Macau
  • Guest Researcher, Austrian Institute of Technology

Teaching

Graduate Courses

  • Introduction to Research in Medical Administration (CMED710)
  • Research Methodology (CMED729)
  • Across the Gap between Science and Industry (CMED725)
  • Advanced topics in Medicinal Administration (CMED825)

Research

Research Interests

  • Complex systems analysis
  • Medical data mining
  • Pharmaceutical innovation management

Research Team

  • Postdoctoral Fellow
    Scherngell; L. Su;
  • PhD Candidate
    J.Y. Ni; Q.R. Zhang; X.J. Kong; H.H. Lin; H.L. Zuo; K.M. Liu; N. Yang; D.N. Yao; Z.H. Wang;
  • Master Students
    Y. Guo; S.N. Man; H.W. Kuok; J.C. Xu; F. Ding; H. You; C.J. Huang; S.Q. Tian; I.T. Ng; C. Cao; X.M. Geng; H.Y. Liang; J.L. Deng; J.R. Zhao; K.W. Si Tou; M. Wan; P.P. Li; B.Y. Zhang; Q.W. Yuan; J.F. Zhu; J.W. Qu; G.Y. Li; I.L. Chio;

In terms of the increasing importance of multidisciplinary collaborations in a changing knowledge world, students and researchers majored in Pharmacy, Chinese Medicines, Biotechnology, Informatics, Economics, Management, or related subjects are highly encouraged to apply for PhD programs, Master programs, Postdoctoral Fellow, or Research Assistants to join our research team. For further information, please contact Dr. Hu at yuanjiahu@um.edu.mo.


Selected Publications

Journals (total, 138; * corresponding author)

  1. H.L. Zuo, Q.R. Zhang, S.B. Su, Q.L. Chen, F.Q. Yang*, Y.J. Hu*, A network pharmacology-based approach to analyse potential targets of traditional herbal formulas: An example of Yu Ping Feng decoction, Scientific Reports, 8: 11418, 2018.
  2. H.H. Lin, D.F. Ouyang, Y.J. Hu*, Intelligent Classifier: A Tool to Impel Drug Technology Transfer from Academia to Industry, Journal of Pharmaceutical Innovation, 1-8, 2018.
  3. K.M. Liu, H.H. Lin, R.B. Pi, S.H. Mak, Y.F. Han, Y.J. Hu*, Research and development of anti-Alzheimer’s disease drugs: an update from the perspective of technology flows, Expert opinion on therapeutic patents, 28(4): 341-350, 2018.
  4. X.J. Kong, Q.R. Zhang, Y.F. Lai, H. Hu, X. Chen,Y.J. Hu*, Global patent landscape of programmed cell death 1: implications of the rapid expansion. Expert Opinion on Therapeutic Patents, 28(1): 69-80, 2018.
  5. H.H. Lin, L.L. Zhang, Y. Ru, J.J. Lu*, Y.J. Hu*, Network analysis of drug-target interactions: A study on FDA-approved New Molecular Entities between 2000 to 2015, Scientific Reports, 7: 12230, 2017.
  6. X.J. Kong, J.B. Wan, H. Hu, S.B. Su, Y.J. Hu*, Evolving patterns in a collaboration network of global R&D on monoclonal antibodies, MAbs, 9(7): 1041-1051, 2017.
  7. Q.R. Zhang, H. Yu, J. Qi, D.S. Tang, X.J. Chen, J.B. Wan, P. Li, H. Hu, Y.T. Wang, Y.J. Hu*, Natural formulas and the nature of formulas: Exploring potential therapeutic targets based on traditional Chinese herbal formulas, Plos One, 12(2): 1-14, 2017.
  8. Q.R. Zhang, X.J. Kong, H.Y. Xu, Y.T. Wang, Y.J. Hu*, Progress of studies on traditional Chinese medicine-based on complex network analysis, World Journal of Traditional Chinese Medicine, 3: 1-10, 2017.
  9. J.Y. Ni, J.R. Zhao, C.O.L Ung, Y.J. Hu*, H. Hu, Y.T. Wang, Obstacles and opportunities in Chinese pharmaceutical innovation, Globalization and Health, 13(1): 1-9, 2017.
  10. J.L. Deng, K.W. Sitou, Y.P. Zhang, R.Yan, Y.J. Hu*, Analyzing the Chinese landscape in anti-diabetic drug research: leading knowledge production institutions and thematic communities, Chinese Medicine, 11: 13, 2016.
  11. J.Y. Ni, J. B. Wan, X.J. Kong, Y. Cai, F.Q. Yang, Y.T. Wang, Y.J. Hu*, Pharmaceutical technology licensing: An analysis in the field of cardiovascular disease, Journal of Pharmaceutical Innovation, 11(1): 34-45, 2016.
  12. M. Zhang, X.J. Kong, J. Zheng, J.B. Wan, Y.T. Wang, Y.J. Hu*, R. Shao, Research and development of antibiotics: insights from patents and citation network, Expert Opinion on Therapeutic Patents, 26: 617-627, 2016.
  13. F. Ding, Q.R. Zhang, C.O.L. Ung, Y.T. Wang, Y.F. Han, Y.J. Hu*, J. Qi, An analysis of chemical ingredients network of Chinese herbal formulae for the treatment of coronary heart disease, Plos One, 10(2): e0116441, 2015.
  14. X.J. Kong, Y.J. Hu*, Z.F. Cai, F.Q. Yang, Q.R. Zhang, Dendritic-cell-based technology landscape: Insights from patents and citation networks, Human Vaccines & Immunotherapeutics, 11(3):682-688, 2015.
  15. X.J. Kong, W.X. Zhou, J.B. Wan, Q.R. Zhang, J.Y. Ni, Y.J. Hu*, An integrative thrombosis network: Visualization and topological analysis. Evidence-Based Complementary and Alternative Medicine, 2: 265303, 2015.
  16. H. You., M. Barber, T. Scherngell, J.Y. Ni, Y.J. Hu*, China’s landscape in oncology drug research: Perspectives from research collaboration networks. Chinese Journal of Cancer Research, 27(2):138-147, 2015.
  17. Y.J. Hu, T. Scherngell, L. Qiu, Y.T. Wang, R&D internationalisation patterns in the global pharmaceutical industry: Evidence from a network analytic perspective. Technology Analysis & Strategic Management, 27(5):532-549, 2015.
  18. J.Y. Ni, R. Shao, C.O.L. Ung, Y.T. Wang, Y.J Hu*, Y. Cai, Valuation of pharmaceutical patents: A comprehensive analytical framework based on technological, commercial, and legal factors. Journal of Pharmaceutical Innovation, 10(3):281-285, 2015.
  19. X.M. Geng, X.J. Kong, H. Hu, J.Y. Chen, F.Q. Yang, H.Y. Liang, X. Chen, Y.J. Hu*, Research and development of therapeutic mAbs: An analysis based on pipeline projects, Human Vaccines & Immunotherapeutics, 11(12):2769-2776, 2015.
  20. J.C. Xu, X. J. Kong, L. Qiu, X. M. Geng, Y.J. Hu*, Y.T. Wang, Research and development of anti-Alzheimer’s drugs: An analysis based on technology flows measured by patent citations, Expert Opinion on Therapeutic Patents, 7: 1-10, 2014.
  21. T. Scherngell, M. Borowiecki, Y.J. Hu*, Effects of knowledge capital on total factor productivity in China: a spatial econometric perspective, China Economic Review, 29: 82-94, 2014.
  22. Y.J. Hu*, T. Scherngell, S. N. Man, Y.T. Wang, Is the United States still dominant in the global pharmaceutical innovation network? Plos One, 8(11), e77247, 2013.
  23. Y. Guo, Y.J. Hu*, Y.T. Wang, Patent indicators: A window on pharmaceutical market value, Expert Opinion on Therapeutic Patents, 6: 1-6, 2013.
  24. J.Y. Ni, J.C. Xu, Y.J. Hu*, L. Su, Y.T. Wang, Cross-regional pharmaceutical technology transfer in China: Patterns and proposed investment strategies, Therapeutic Innovation & Regulatory Science, 8: 1-10, 2013.
  25. J.J. Lu, W. Pan, Y.J. Hu*, Y.T. Wang*, Multi-target drugs: The trend of drug research and development, Plos One, 7(6): 1-6, 2012. (ESI Highly Cited Paper)
  26. T. Scherngell and Y.J. Hu, Collaborative knowledge production in China: Regional evidence from a gravity model approach, Regional Studies, 45: 755-772, 2011.
  27. Y.J. Hu, Y. Bian, Y.T. Wang, Opening the “black box” of pharmaceutical patent value: An empirical analysis, Drug Information Journal, 42(6): 561-568, 2008.
  28. Y.J. Hu, C. O. L. Ung, Y. Bian, Y.T. Wang, The Chinese pharmaceutical market: Dynamics and a proposed investment strategy, Journal of Medical Marketing, 7(1): 18-24, 2007. (Best Paper Award)
  29. Y.J. Hu, F. Geng, Y. Bian, Y.T. Wang, The Chinese pharmaceutical market: Perspectives of the health consumer, Journal of Medical Marketing, 7(4): 295-300, 2007.
  30. Y.J. Hu, Y. Bian, Y.T. Wang, Secrets of blockbuster drugs: Data mining for oppositions against patents, Drug Information Journal, 41(3): 425, 2007.

Book Chapters

  1. Y.T. Wang, Y.J. Hu, A.W.K. Chan, Innovation Value Chain of Chinese Pharmaceuticals, United States-China Intellectual Property Institute, New York, 2017.
  2. H.H Lin, P.P Li, X.J. Kong, J. Cai, S.B. Su, Y.J. Hu*, An analysis of evolutionary conservation based on genomic orthology and protein-protein interaction networks, in Biotechnology in Hong Kong III, United States-China Intellectual Property Institute, Hong Kong, 2017.
  3. K.W. Sitou, J.B. Wan, M.S.H. Mak, Y.F. Han, Y.J. Hu*, Monitoring drug research on clinical neurology in china: an analysis of institutional leaders and community themes, in Innovation Value Chain of Chinese Pharmaceuticals, United States-China Intellectual Property Institute, New York, 2017, Chapter 3.
  4. H.W. Kuok, X.J. Kong, Y.J. Hu*, Y.T. Wang*, China’s landscape of discovering mirnas in cancer, in Innovation Value Chain of Chinese Pharmaceuticals, United States-China Intellectual Property Institute, New York, 2017, Chapter 4.
  5. X.J. Kong, H Lu, Q.R. Zhang, H.L. Zuo, Y.J. Hu*, A.W. Chan*, Global landscape of research and development on antibiotics, in Innovation Value Chain of Chinese Pharmaceuticals, United States-China Intellectual Property Institute, New York, 2017, Chapter 5.
  6. X.J. Kong, H.Y. Liang, Q.W. Yuan, Y.J. Hu*, Entry inhibitors for aids therapy: a review of research and development projects, in Innovation Value Chain of Chinese Pharmaceuticals, United States-China Intellectual Property Institute, New York, 2017, Chapter 6.
  7. T.H. Yin, X.J. Kong, Y.T. Wang, X. Chen, Y.J. Hu*, R. Shao*, Collaboration networks for R&D of monoclonal antibodies: an analysis based on pipeline projects, in Innovation Value Chain of Chinese Pharmaceuticals, United States-China Intellectual Property Institute, New York, 2017, Chapter 7.
  8. H.H. Lin, S.Q. Tian, M.S.H. Mak, Y.F. Han, Y.J. Hu*, An analysis of technology flows of antidepressants based on patent citation network, in Innovation Value Chain of Chinese Pharmaceuticals, United States-China Intellectual Property Institute, New York, 2017, Chapter 9.
  9. J.Y. Ni, R. Shao, C.O.L. Ung, Y.T. Wang, Y.J. Hu*, Y. Cai, Pharmaceutical patent valuation based on empirical models, in Innovation Value Chain of Chinese Pharmaceuticals, United States-China Intellectual Property Institute, New York, 2017, Chapter 10.
  10. J.Y. Ni, Y.J. Hu*, J.B. Wan, T. Scherngell, F. Kwan, Cross-regional pharmaceutical technology transfer in china: an empirical study based on spatial interaction model, in Innovation Value Chain of Chinese Pharmaceuticals, United States-China Intellectual Property Institute, New York, 2017, Chapter 11.
  11. M. Wan, J.R. Zhao, B.Y. Zhang, D.N. Yao, Y.J. Hu*, Changing pharmaceutical registration rules in china: latest updates and potential impacts, in Innovation Value Chain of Chinese Pharmaceuticals, United States-China Intellectual Property Institute, New York, 2017, Chapter 12.
  12. P.P. Li, H.H. Lin, Y.J. Hu*, Pharmaceutical innovation network: global patterns and the role of China. Innovation Value Chain of Chinese Pharmaceuticals, in Innovation Value Chain of Chinese Pharmaceuticals, United States-China Intellectual Property Institute, New York, 2017, Chapter 13.
  13. H.W. Kuok, X.J. Kong, Y.J. Hu*, Y.T. Wang, Discovering mirnas in cancer: China’s landscape and the role of Hong Kong, in Biotechnology in Hong Kong, United States-China Intellectual Property Institute, Hong Kong, 2015, Chapter 2.
  14. Y.Y. Yu, J.J. Liu, L. Qiu, W. Pan, Y.J. Hu, Y.T. Wang, Situation and Outlook on the Market and Intellectual Properties of Anti-cancer Chinese Medicines, in Technologies and Progresses of Advanced Research on Anti-cancer Chinese Medicines, People’s Medical Publishing House, Beijing, 2013.
  15. Y.T. Wang, Y. Bian, L. Li, Y.J. Hu, The Development of Macao’s Healthcare, in Annual Report on Economy and Society of Macao–Blue Book of Macao 2010, Social Sciences Academic Press, Beijing, 2010.
  16. Y.J. Hu, R. Shao, R.L. Song, Y. Bian, L.W. Shi, Y.T. Wang, A Study on the Industrial Policy Law of Chinese Pharmaceutical Industry, in Chinese Medical Sciences Collection Series A- Progress in Medicinal Administration Research, University of Macau Publisher, Macau, 2005.

Conferences and Awards

  1. Exploring outcomes of university licensing: An empirical study based on patents of drug development, The 16th Meeting of Consortium for Globalization of Chinese Medicine, Guangzhou, August 2017. (Conference Grant)
  2. International development of Chinese medicines in European union: An analysis based on market and registration, The 16th Meeting of Consortium for Globalization of Chinese Medicine, Guangzhou, August 2017. (Conference Grant)
  3. The 3rd Summer Summit of World Congress of Chinese Medicine, World Federation of Chinese Medicine Societies, Hefei, China, June 2017.
  4. Pharmaceutical co-innovation network: Global patterns and the role of China, The 1st National Academic Forum for Postgraduates of Pharmacy, Nanjing, May 2017. (First Prize for Oral Presentation, Conference Grant)
  5. Patent valuation: Case study on pharmaceutical patents in China, WIPO-WTO Colloquium for IP Teachers, Geneva, June 13 to 24, 2016. (Conference Grant)
  6. Study on therapeutic targets networks of Xuefu-zhuyu decoction and Gualou-xiebai-banxia decoction for the treatment of coronary artery disease, 13th Annual Conference of Chinese Pharmacological Society, Beijing, November 2015.
  7. Network-based identification of therapeutic targets from traditional herbal formulae, 7th Asian Association of Schools of Pharmacy (AASP) Conference, Taipei, Taiwan, October 2015.
  8. Valuation of Pharmaceutical Patents: A Comprehensive Analytical Framework Based on Technological, Commercial, and Legal Factors, Law School of South China University of Technology, Guangzhou, October 16, 2015.
  9. Cross-regional pharmaceutical development in China: An empirical study based on technology transfer, 14th Meeting of Consortium for Globalization of Chinese Medicine (CGCM), London ON, Canada, August 2015.
  10. An introduction to network analysis, The Fourth Salon of Young Scientists of Traditional Chinese Medicine, China Journal of Chinese Materia Medica & Beijing University of Chinese Medicine, Beijing, April 2015.
  11. Strategies on China’s pharmaceutical innovation from perspective of technology transfer, The 10th Postgraduate Forum of Social and Administrative Pharmacy of China, Nanjing, November 2014 (Best Paper Award).
  12. Patent: A powerful indicator to measure drug innovation, Annual Meeting of Law Offices of Albert Wai-Kit Chan, Hong Kong, August 2014.
  13. Innovation, knowledge spillovers and economic productivity in China, Jointresearch Grant of Eurasia Pacific Uninet (EPU), Austria, 2013-2014.
  14. Effects of knowledge capital on total factor productivity in China: A spatial econometric perspective, The 53rd European Regional Science Association Congress, Palermo, Italy, August 2013.
  15. Correlation between drug licensing and economic output: evidence from 151 drugs marketed in USA? The 24th Annual EuroMeeting of Drug Information Association, Copenhagen, Denmark, March 2012.
  16. R&D collaboration networks of Chinese universities in medical field: An empirical analysis based on informetrics, 2011 IEEE International Symposium on IT in Medicine & Education, Guangzhou, China, December 2011.
  17. Empirical Study on the Impact of ERP and Performance of Listed Pharmaceutical Companies in China (ISTP), 2011 2nd International Conference on Management Science and Engineering, Chengdu, October 2011.
  18. Decoding Business Strategies of Big Pharms in Chinese Medical Market: An Empirical Study based on Product and Patent Statistics (ISTP), 2011 2nd International Conference on Management Science and Engineering, Chengdu, October 2011.
  19. What determines pharmaceutical business value: evidence from 127 drugs marketed in USA? 10th Meeting of Consortium for Globalization of Chinese Medicine, Shanghai, August 2011.
  20. Pharmaceutical patent valuation: Novel models and applications in industry, The 46th Annual Meeting of U.S. Drug Information Association, Washington, D.C. USA, June 2010. (Session Chair, Conference Grant)
  21. Pharmaceutical patent valuation, Exchange Grant of Eurasia Pacific Uninet (EPU), Austria, 2008-2009.
  22. Secrets of Blockbuster Drugs–Data Mining for Oppositions against Patents, The 43rd Annual Meeting of U.S. Drug Information Association, Atlanta, USA, June 2007. (Conference Grant)
  23. Study on the Correlation between Blockbuster Drugs and Oppositions against their Patents, 2007 Hong Kong-Macau Postgraduate Symposium on Chinese Medicine, Hong Kong, June 2007.
  24. A look at China’s pharmaceutical market, A Workshop on New Paradigms in Life Sciences Marketing by European Business School INSEAD, Paris, France, March 2007. (Conference Grant)
  25. The International Development of Chinese Medicine under the consideration of the management perspectives, The 9th International Congress on Ethnopharmacology, Nanning, August 2006.
  26. The Distribution Pattern and Reasons of Pharmaceutical Industry in China, Asia-Pacific Traditional Medicine Expo & Forum, Wuhan, October 2005.
  27. Study on the Chinese Medicine Industry Map, 2005 Hong Kong-Macau Postgraduate Symposium on Chinese Medicine, Hong Kong, August 2005.
  28. The Propagation and Innovation of Chinese Traditional Culture from the Medical Dimension, Conference for the Propagation and Innovation of Chinese Traditional Culture, Shanghai, July 2005.

Academic Services

  1. Policy Expert, State Intellectual Property Operation Public Service Platform, Financial Innovation Pilot Platform, 2018 – Present
  2. Arbitrator, Zhuhai Arbitration Commission, 2018 – Present
  3. Project Researcher, The Research Center of National Drug Policy & Ecosystem, 2015 – Present
  4. Deputy Secretary-General, Specialty Committee on Network Pharmacology, World Federation of Chinese Medicine Societies, 2015 – Present
  5. Council Member, Specialty Committee of Information, World Federation of Chinese Medicine Societies, 2015 – Present
  6. Founding Commissioner, Commission on Network Pharmacology, Chinese Pharmacological Society, 2014 – Present
  7. Researcher, International Research Center of Medicinal Administration, Peking University, 2013 – Present

Contact Details

Institute of Chinese Medical Sciences
University of Macau
Avenida da Universidade, Taipa,
Macao, China

Office: Room 2053, N22
Telephone: (853) 8822-8507
Fax: (853) 2884-1358
E-mail address: yuanjiahu@um.edu.mo